Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2009 1
2010 3
2011 3
2012 5
2013 11
2014 10
2015 3
2016 3
2017 1
2018 2
2020 2
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
Bodei L, Modlin IM, Luster M, Forrer F, Cremonesi M, Hicks RJ, Ezziddin S, Kidd M, Chiti A. Bodei L, et al. Endocr Relat Cancer. 2016 Aug;23(8):C1-7. doi: 10.1530/ERC-16-0258. Epub 2016 Jun 28. Endocr Relat Cancer. 2016. PMID: 27353035
Peptide receptor radionuclide therapy (PRRT) with (90)Y-octreotide or (177)Lu-octreotate is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic or bronchopulmonary NETs. PRRT …
Peptide receptor radionuclide therapy (PRRT) with (90)Y-octreotide or (177)Lu-octreotate is an effective treatment for inoperable or …
[Neuroendocrine neoplasms of the breast].
Anlauf M, Neumann M, Bomberg S, Luczak K, Heikaus S, Gustmann C, Antke C, Ezziddin S, Fottner C, Pavel M, Pape UF, Rinke A, Lahner H, Schott M, Cremer B, Hörsch D, Baum RP, Groh U, Alkatout I, Rudlowski C, Scheler P, Zirbes TK, Hoffmann J, Fehm T, Gabbert HE, Baldus SE. Anlauf M, et al. Pathologe. 2015 May;36(3):261-70. doi: 10.1007/s00292-015-0024-0. Pathologe. 2015. PMID: 25986886 Review. German.
Neuroendocrine neoplasms (NEN) of the breast are specific tumor entities. According to the literature up to 5% of breast neoplasms are malignant epithelial neoplasms of the breast. They are defined by a neuroendocrine (NE) architecture and cytology combined with an …
Neuroendocrine neoplasms (NEN) of the breast are specific tumor entities. According to the literature up to 5% of breast neoplasms ar …
Advances in Peptide Receptor Radionuclide Therapy.
Sabet A, Biersack HJ, Ezziddin S. Sabet A, et al. Semin Nucl Med. 2016 Jan;46(1):40-6. doi: 10.1053/j.semnuclmed.2015.09.005. Semin Nucl Med. 2016. PMID: 26687856 Review.
Peptide receptor radionuclide therapy (PRRT) is a very effective treatment modality for advanced neuroendocrine tumors (NETs), representing a teaching model for truly targeted antitumor therapy. ...The approach of combining cytotoxic or radiosensitizing drugs with t …
Peptide receptor radionuclide therapy (PRRT) is a very effective treatment modality for advanced neuroendocrine tumors (NETs), …
131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
Grünwald F, Ezziddin S. Grünwald F, et al. Semin Nucl Med. 2010 Mar;40(2):153-63. doi: 10.1053/j.semnuclmed.2009.11.004. Semin Nucl Med. 2010. PMID: 20113683 Review.
Treatment with (131)I-metaiodobenzylguanidine (MIBG) has been introduced to the management of neuroendocrine tumors (NET) nearly 30 years ago. It provides efficient internal radiotherapy of chromaffin tumors (neuroblastoma, pheochromocytoma, and paraganglioma), but also of …
Treatment with (131)I-metaiodobenzylguanidine (MIBG) has been introduced to the management of neuroendocrine tumors (NET) nearly 30 y …
[Neuroendocrine neoplasms of the distal jejunum and ileum].
Anlauf M, Sipos B, Boeck I, Baldus SE, Heikaus S, Krausch M, Knoefel WT, Begum N, Goretzki P, Schott M, Auernhammer CJ, Cremer B, Rinke A, Ezziddin S, Fottner C, Pöpperl G, Lahner H, Hörsch D, Gabbert HE, Komminoth P, Perren A, Klöppel G, Wiedenmann B, Pavel M, Pape U. Anlauf M, et al. Pathologe. 2014 May;35(3):283-93; quiz 294. doi: 10.1007/s00292-013-1888-5. Pathologe. 2014. PMID: 24671468 Free article. Review. German.
Neuroendocrine neoplasms (NEN) of the distal jejunum and ileum derive from serotonin-producing enterochromaffin (EC) cells. ...In order to standardise and improve diagnosis and therapy, the guidelines for the diagnosis and clinical management of jejuno-ileal NEN as well as …
Neuroendocrine neoplasms (NEN) of the distal jejunum and ileum derive from serotonin-producing enterochromaffin (EC) cells. ...In ord …
Radioembolization of liver tumors with yttrium-90 microspheres.
Ahmadzadehfar H, Biersack HJ, Ezziddin S. Ahmadzadehfar H, et al. Semin Nucl Med. 2010 Mar;40(2):105-21. doi: 10.1053/j.semnuclmed.2009.11.001. Semin Nucl Med. 2010. PMID: 20113679 Review.
There is growing evidence for efficiency in liver tumors of various entities, with the most prominent ones being hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors. Hepatic metastases of numerous other tumor entities including breast cancer, cholangioca …
There is growing evidence for efficiency in liver tumors of various entities, with the most prominent ones being hepatocellular carcinoma, c …
Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Pöppel T, Guhlke S, Biersack HJ, Ezziddin S. Sabet A, et al. J Nucl Med. 2013 Nov;54(11):1857-61. doi: 10.2967/jnumed.112.119347. Epub 2013 Sep 5. J Nucl Med. 2013. PMID: 24009272 Free article.
Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide therapy (PRRT). The aim of this study was to investigate the incidence, severity, and reversibility of long-term hematotoxicity in a large cohort of patient undergoing PRRT with (177 …
Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide therapy (PRRT). The aim of this study was to inve …
[Neuroendocrine Neoplasia within the German NET Registry].
Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:. Im Namen aller Teilnehmer/innen am Deutschen NET-Registers, et al. Z Gastroenterol. 2018 Oct;56(10):1237-1246. doi: 10.1055/a-0661-6099. Epub 2018 Oct 10. Z Gastroenterol. 2018. PMID: 30304748 German.
Neuroendocrine neoplasias (NEN) comprise a rare tumor entity with heterogeneous biology, prognosis and therapeutic options. ...In concordance with current guidelines, somatostatin analogues (SSA) and peptide-receptor-radionuclide-therapy (PRRT) were the most common …
Neuroendocrine neoplasias (NEN) comprise a rare tumor entity with heterogeneous biology, prognosis and therapeutic options. ...In con …
90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
Ezziddin S, Meyer C, Kahancova S, Haslerud T, Willinek W, Wilhelm K, Biersack HJ, Ahmadzadehfar H. Ezziddin S, et al. J Nucl Med. 2012 Nov;53(11):1663-9. doi: 10.2967/jnumed.112.107482. Epub 2012 Sep 17. J Nucl Med. 2012. PMID: 22988059 Free article.
Previous radiation therapy of the liver is a contraindication for performing (90)Y microsphere radioembolization, and its safety after internal radiation exposure through peptide receptor radionuclide therapy (PRRT) has not yet been investigated. METHODS: We retrospectivel …
Previous radiation therapy of the liver is a contraindication for performing (90)Y microsphere radioembolization, and its safety after inter …
42 results